{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T08:18:29Z","timestamp":1683793109916},"reference-count":200,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This paper introduces novel therapeutic strategies focusing on a molecular marker relevant to a particular hematologic malignancy. Four different approaches targeting specific molecules in unique pathways will be presented. The common theme will be rational target selection in a strategy that has reached the early phase of human clinical trial in one malignancy, but with a much broader potential applicability to the technology.<\/jats:p><jats:p>In Section I Dr. Richard Klasa presents preclinical data on the use of antisense oligonucleotides directed at the bcl-2 gene message to specifically downregulate Bcl-2 protein expression in non-Hodgkin's lymphomas and render the cells more susceptible to the induction of apoptosis.<\/jats:p><jats:p>In Section II Dr. Alan List reviews the targeting of vascular endothelial growth factor (VEGF) and its receptor in anti-angiogenesis strategies for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).<\/jats:p><jats:p>In Section III Dr. Bruce Cheson describes recent progress in inhibiting cell cycle progression by selectively disrupting cyclin D1 with structurally unique compounds such as flavopiridol in mantle cell lymphoma as well as describing a new class of agents that affect proteasome degradation pathways.<\/jats:p>","DOI":"10.1182\/asheducation-2001.1.443","type":"journal-article","created":{"date-parts":[[2003,8,28]],"date-time":"2003-08-28T00:29:50Z","timestamp":1062030590000},"page":"443-462","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Rational Approaches to Design of Therapeutics Targeting Molecular Markers"],"prefix":"10.1182","volume":"2001","author":[{"given":"Richard J.","family":"Klasa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan F.","family":"List","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021223261107300_R1","doi-asserted-by":"crossref","unstructured":"Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503.","DOI":"10.1038\/35000501"},{"key":"2020021223261107300_R2","unstructured":"Ong ST, Le Beau MM. Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma. Semin Oncol. 1998;25:447."},{"key":"2020021223261107300_R3","doi-asserted-by":"crossref","unstructured":"Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997;90:244.","DOI":"10.1182\/blood.V90.1.244"},{"key":"2020021223261107300_R4","unstructured":"Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol. 1997;34:9."},{"key":"2020021223261107300_R5","doi-asserted-by":"crossref","unstructured":"Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 1996;88:386.","DOI":"10.1182\/blood.V88.2.386.bloodjournal882386"},{"key":"2020021223261107300_R6","doi-asserted-by":"crossref","unstructured":"Reed JC. Double identity for proteins of the Bcl-2 family. Nature. 1997;387:773.","DOI":"10.1038\/42867"},{"key":"2020021223261107300_R7","doi-asserted-by":"crossref","unstructured":"Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1978;75:280.","DOI":"10.1073\/pnas.75.1.280"},{"key":"2020021223261107300_R8","doi-asserted-by":"crossref","unstructured":"Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A. 1978;75:285.","DOI":"10.1073\/pnas.75.1.285"},{"key":"2020021223261107300_R9","doi-asserted-by":"crossref","unstructured":"Mizuno T, Chou MY, Inouye M. A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (micRNA). Proc Natl Acad Sci U S A. 1984;81:1966.","DOI":"10.1073\/pnas.81.7.1966"},{"key":"2020021223261107300_R10","doi-asserted-by":"crossref","unstructured":"Izant JG, Weintraub H. Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis. Cell. 1984;36:1007.","DOI":"10.1016\/0092-8674(84)90050-3"},{"key":"2020021223261107300_R11","doi-asserted-by":"crossref","unstructured":"Wintersberger U. Ribonucleases H of retroviral and cellular origin. Pharmacology & Therapeutics. 1990;48:259.","DOI":"10.1016\/0163-7258(90)90083-E"},{"key":"2020021223261107300_R12","doi-asserted-by":"crossref","unstructured":"Sohail M, Hochegger H, Klotzbucher A, Guellec RL, Hunt T, Southern EM. Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo. Nucleic Acids Res. 2001;29:2041.","DOI":"10.1093\/nar\/29.10.2041"},{"key":"2020021223261107300_R13","doi-asserted-by":"crossref","unstructured":"Ho SP, Bao Y, Lesher T, et al. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat Biotechnol. 1998;16:59.","DOI":"10.1038\/nbt0198-59"},{"key":"2020021223261107300_R14","doi-asserted-by":"crossref","unstructured":"Ho SP, Britton DH, Stone BA, et al. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res. 1996;24:1901.","DOI":"10.1093\/nar\/24.10.1901"},{"key":"2020021223261107300_R15","doi-asserted-by":"crossref","unstructured":"Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991;88:7595.","DOI":"10.1073\/pnas.88.17.7595"},{"key":"2020021223261107300_R16","unstructured":"Raynaud FI, Orr RM, Goddard PM, et al. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther. 1997;281:420."},{"key":"2020021223261107300_R17","doi-asserted-by":"crossref","unstructured":"Jansen B, Schlagbauer-Wadl H, Brown BD, et al. bcl-2 antisense therapy chemosensitizes human melanoma in Scid mice. Nat Med. 1998;4:232.","DOI":"10.1038\/nm0298-232"},{"key":"2020021223261107300_R18","doi-asserted-by":"crossref","unstructured":"Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase [see comments]. Nat Med. 1996;2:668.","DOI":"10.1038\/nm0696-668"},{"key":"2020021223261107300_R19","doi-asserted-by":"crossref","unstructured":"Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997;94:10833.","DOI":"10.1073\/pnas.94.20.10833"},{"key":"2020021223261107300_R20","doi-asserted-by":"crossref","unstructured":"Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997;89:2994.","DOI":"10.1182\/blood.V89.8.2994"},{"key":"2020021223261107300_R21","doi-asserted-by":"crossref","unstructured":"Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol. 1996;157:1840.","DOI":"10.4049\/jimmunol.157.5.1840"},{"key":"2020021223261107300_R22","doi-asserted-by":"crossref","unstructured":"Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546.","DOI":"10.1038\/374546a0"},{"key":"2020021223261107300_R23","doi-asserted-by":"crossref","unstructured":"Saijo Y, Uchiyama B, Abe T, Satoh K, Nukiwa T. Contiguous four-guanosine sequence in c-myc antisense phosphorothioate oligonucleotides inhibits cell growth on human lung cancer cells: possible involvement of cell adhesion inhibition. Jpn J Cancer Res. 1997;88:26.","DOI":"10.1111\/j.1349-7006.1997.tb00297.x"},{"key":"2020021223261107300_R24","doi-asserted-by":"crossref","unstructured":"Buckheit RW Jr, Roberson JL, Lackman-Smith C, Wyatt JR, Vickers TA, Ecker DJ. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res Hum Retroviruses. 1994;10:","DOI":"10.1089\/aid.1994.10.1497"},{"key":"2020021223261107300_R25","unstructured":"Cotter FE, Johnson P, Hall P, et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene. 1994;9:3049."},{"key":"2020021223261107300_R26","doi-asserted-by":"crossref","unstructured":"Cotter FE. Antisense therapy for lymphomas. Hematol Oncol. 1997;15:3.","DOI":"10.1002\/(SICI)1099-1069(199702)15:1<3::AID-HON583>3.0.CO;2-S"},{"key":"2020021223261107300_R27","doi-asserted-by":"crossref","unstructured":"Reed JC, Miyashita T, Takayama S, et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem. 1996;60:23.","DOI":"10.1002\/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.0.CO;2-5"},{"key":"2020021223261107300_R28","doi-asserted-by":"crossref","unstructured":"Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol. Clin North Am. 1995;9:451.","DOI":"10.1016\/S0889-8588(18)30104-7"},{"key":"2020021223261107300_R29","unstructured":"Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and Wehi7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 1992;52:5407."},{"key":"2020021223261107300_R30","doi-asserted-by":"crossref","unstructured":"Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993;81:151.","DOI":"10.1182\/blood.V81.1.151.151"},{"key":"2020021223261107300_R31","unstructured":"Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair [published erratum appears in Cancer Res 1994 Jun 1;54(11):3074]. Cancer Res. 1993;53:4251."},{"key":"2020021223261107300_R32","unstructured":"Walton MI, Whysong D, PM OC, Hockenbery D, Korsmeyer SJ, Kohn KW. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 1993;53:1853."},{"key":"2020021223261107300_R33","doi-asserted-by":"crossref","unstructured":"Reed JC, Kitada S, Takayama S, Miyashita T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol. 1994;5:61.","DOI":"10.1093\/annonc\/5.suppl_1.S61"},{"key":"2020021223261107300_R34","unstructured":"Keith FJ, Bradbury DA, Zhu YM, Russell NH. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia. 1995;9:131."},{"key":"2020021223261107300_R35","unstructured":"Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res. 2000;6:2492."},{"key":"2020021223261107300_R36","unstructured":"Dyer MJ, Lillington DM, Bastard C, et al. Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus. Leukemia. 1996;10:1198."},{"key":"2020021223261107300_R37","doi-asserted-by":"crossref","unstructured":"Macpherson N, Lesack D, Klasa R, et al. Small noncleaved, non-Burkitt's (Burkitt-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol. 1999;17:1558.","DOI":"10.1200\/JCO.1999.17.5.1558"},{"key":"2020021223261107300_R38","doi-asserted-by":"crossref","unstructured":"Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997;349:1137.","DOI":"10.1016\/S0140-6736(96)11103-X"},{"key":"2020021223261107300_R39","doi-asserted-by":"crossref","unstructured":"Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2000;18:1812.","DOI":"10.1200\/JCO.2000.18.9.1812"},{"key":"2020021223261107300_R40","doi-asserted-by":"crossref","unstructured":"Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet. 2000;356:1728.","DOI":"10.1016\/S0140-6736(00)03207-4"},{"key":"2020021223261107300_R41","doi-asserted-by":"crossref","unstructured":"Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277:48\u201350.","DOI":"10.1126\/science.277.5322.48"},{"key":"2020021223261107300_R42","doi-asserted-by":"crossref","unstructured":"Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671\u2013674.","DOI":"10.1038\/386671a0"},{"key":"2020021223261107300_R43","doi-asserted-by":"crossref","unstructured":"Liekens S, DeClercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochemical Pharmacology. 2001;61:253\u2013270.","DOI":"10.1016\/S0006-2952(00)00529-3"},{"key":"2020021223261107300_R44","doi-asserted-by":"crossref","unstructured":"Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306\u20131309.","DOI":"10.1126\/science.2479986"},{"key":"2020021223261107300_R45","doi-asserted-by":"crossref","unstructured":"Folkman J. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757\u20131763.","DOI":"10.1056\/NEJM199512283332608"},{"key":"2020021223261107300_R46","doi-asserted-by":"crossref","unstructured":"Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991:266:11947\u201311954.","DOI":"10.1016\/S0021-9258(18)99049-6"},{"key":"2020021223261107300_R47","doi-asserted-by":"crossref","unstructured":"Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface associated heparin-like molecules. J Biol Chem. 1992;267:6093\u20136098.","DOI":"10.1016\/S0021-9258(18)42666-X"},{"key":"2020021223261107300_R48","doi-asserted-by":"crossref","unstructured":"Roberts R, Gallagher J, Spooncer E, Allen TD, Bloomfield F, Dexter RM. Heparan-sulfate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature. 1998;332:376\u2013378.","DOI":"10.1038\/332376a0"},{"key":"2020021223261107300_R49","doi-asserted-by":"crossref","unstructured":"Keyt BA, Berleau LT, Nguyen HV. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem. 1996;271:7788\u20137795.","DOI":"10.1074\/jbc.271.13.7788"},{"key":"2020021223261107300_R50","doi-asserted-by":"crossref","unstructured":"Soker S, Gollamudi-Payne S, Fidder H, Charmahelli H, Klagbrun M. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. J Biol Chem. 1997;272:31582\u201331588.","DOI":"10.1074\/jbc.272.50.31582"},{"key":"2020021223261107300_R51","doi-asserted-by":"crossref","unstructured":"Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 1994;90:649\u2013652.","DOI":"10.1161\/01.CIR.90.2.649"},{"key":"2020021223261107300_R52","doi-asserted-by":"crossref","unstructured":"Namiki A, Brogi E, Kearney M, et al. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem. 1995;270:31189\u201331195.","DOI":"10.1074\/jbc.270.52.31189"},{"key":"2020021223261107300_R53","doi-asserted-by":"crossref","unstructured":"Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation. 1996;94:1647\u20131654.","DOI":"10.1161\/01.CIR.94.7.1647"},{"key":"2020021223261107300_R54","doi-asserted-by":"crossref","unstructured":"De Vries C, Escobeo JA, Ueno H, Houck K, Ferarra N, Williams LT. The fms-like tyrosine kinase receptor, a receptor for vascular endothelial growth factor. Science. 1992;255:989\u2013991.","DOI":"10.1126\/science.1312256"},{"key":"2020021223261107300_R55","doi-asserted-by":"crossref","unstructured":"Terman BL, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 1992:187:1579\u20131586.","DOI":"10.1016\/0006-291X(92)90483-2"},{"key":"2020021223261107300_R56","doi-asserted-by":"crossref","unstructured":"Hamada K, Oike Y, Nobuyuki T, et al. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood. 2000;96:3793\u20133800.","DOI":"10.1182\/blood.V96.12.3793"},{"key":"2020021223261107300_R57","doi-asserted-by":"crossref","unstructured":"Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996:15:290\u2013298.","DOI":"10.1002\/j.1460-2075.1996.tb00359.x"},{"key":"2020021223261107300_R58","doi-asserted-by":"crossref","unstructured":"Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin C-H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994;269:26988\u201326995.","DOI":"10.1016\/S0021-9258(18)47116-5"},{"key":"2020021223261107300_R59","unstructured":"Pajusola K, Aprelikova O, Pelicci G, Weich H, Claesson-Welsh L, Alitalo K. Signaling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene. 1994:9:3545\u20133555."},{"key":"2020021223261107300_R60","unstructured":"Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor (VEGF) and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728\u2013733."},{"key":"2020021223261107300_R61","doi-asserted-by":"crossref","unstructured":"Ziegler BL, Valtieri M, Porada GA, et al. KDR receptor: a key marker defining hematopoietic stem cells. Science. 1999;285:1553\u20131558.","DOI":"10.1126\/science.285.5433.1553"},{"key":"2020021223261107300_R62","doi-asserted-by":"crossref","unstructured":"Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87:3336\u20133343.","DOI":"10.1182\/blood.V87.8.3336.bloodjournal8783336"},{"key":"2020021223261107300_R63","doi-asserted-by":"crossref","unstructured":"Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, Shibuya M. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood. 2001:97:785\u2013791.","DOI":"10.1182\/blood.V97.3.785"},{"key":"2020021223261107300_R64","doi-asserted-by":"crossref","unstructured":"Kaipainen A, Korhonen J. Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995;92:3566\u20133570.","DOI":"10.1073\/pnas.92.8.3566"},{"key":"2020021223261107300_R65","doi-asserted-by":"crossref","unstructured":"Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435\u2013439.","DOI":"10.1038\/380435a0"},{"key":"2020021223261107300_R66","doi-asserted-by":"crossref","unstructured":"Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439\u2013442.","DOI":"10.1038\/380439a0"},{"key":"2020021223261107300_R67","doi-asserted-by":"crossref","unstructured":"Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62\u201366.","DOI":"10.1038\/376062a0"},{"key":"2020021223261107300_R68","doi-asserted-by":"crossref","unstructured":"Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A. 1998;95:9349\u20139354.","DOI":"10.1073\/pnas.95.16.9349"},{"key":"2020021223261107300_R69","doi-asserted-by":"crossref","unstructured":"Kukk E, Lymboussaki A, Taira S, et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development. 1996;122:3829\u20133837.","DOI":"10.1242\/dev.122.12.3829"},{"key":"2020021223261107300_R70","doi-asserted-by":"crossref","unstructured":"Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (FLK1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998;95:548\u2013553.","DOI":"10.1073\/pnas.95.2.548"},{"key":"2020021223261107300_R71","doi-asserted-by":"crossref","unstructured":"Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A. 1998;95:11709\u201311714.","DOI":"10.1073\/pnas.95.20.11709"},{"key":"2020021223261107300_R72","doi-asserted-by":"crossref","unstructured":"Meyer M, Clauss M, Lepple-Wienhues A, et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signaling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 1999;18:363\u2013374.","DOI":"10.1093\/emboj\/18.2.363"},{"key":"2020021223261107300_R73","doi-asserted-by":"crossref","unstructured":"Yamada Y, Takakura N, Yasue H, Ogawa H, Fujisawa H, Suda T. Exogenous clustered neuropilin 1 enhances vasculogenesis and angiogenesis. Blood. 2001;97:1671\u20131678.","DOI":"10.1182\/blood.V97.6.1671"},{"key":"2020021223261107300_R74","unstructured":"Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Research. 2000;60:203\u2013212."},{"key":"2020021223261107300_R75","doi-asserted-by":"crossref","unstructured":"Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem. 1997;272:32521\u201332527.","DOI":"10.1074\/jbc.272.51.32521"},{"key":"2020021223261107300_R76","doi-asserted-by":"crossref","unstructured":"Igarashi K, Shigeta K, Isohara T, Yaman T, Uno I. Sck interacts with KDR and Flt1 via its SH2 domain. Biochm Biophys Res Commun. 1998;251:77\u201382.","DOI":"10.1006\/bbrc.1998.9442"},{"key":"2020021223261107300_R77","doi-asserted-by":"crossref","unstructured":"Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-independent Rad-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 1999;18;2221-2230.","DOI":"10.1038\/sj.onc.1202527"},{"key":"2020021223261107300_R78","doi-asserted-by":"crossref","unstructured":"Igarashi K, Isohara T, Kato T, Shigeta K, Yamano T, Uno I. Tryrosine 1213 of Flt1 is a major binding site of Nck and SHP-2. Biochem Biophys Res Commun. 1998;246:95\u201399.","DOI":"10.1006\/bbrc.1998.8578"},{"key":"2020021223261107300_R79","doi-asserted-by":"crossref","unstructured":"Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Investig. 1996;98:2018\u20132026.","DOI":"10.1172\/JCI119006"},{"key":"2020021223261107300_R80","doi-asserted-by":"crossref","unstructured":"Gerber H-P, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase\/Akt signal transduction pathway. J Biol Chem. 1998;273:30336\u201330343.","DOI":"10.1074\/jbc.273.46.30336"},{"key":"2020021223261107300_R81","doi-asserted-by":"crossref","unstructured":"Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J. 1998;335:1\u201313.","DOI":"10.1042\/bj3350001"},{"key":"2020021223261107300_R82","doi-asserted-by":"crossref","unstructured":"Liu ZY, Ganju RK, Wang JF, et al. Characterization of signal transduction pathways in human bone marrow endothelial cells. Blood. 1997;90:2253\u20132259.","DOI":"10.1182\/blood.V90.6.2253"},{"key":"2020021223261107300_R83","doi-asserted-by":"crossref","unstructured":"Byzova T, Goldman C, Pampori N, et al. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Molecular Cell. 2000;6:851\u2013860.","DOI":"10.1016\/S1097-2765(00)00083-6"},{"key":"2020021223261107300_R84","doi-asserted-by":"crossref","unstructured":"Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of \u03b1v\u03b23 in the activation of vascular endothelial growth factor receptor-2. EMBO. 1999;18:882\u2013892.","DOI":"10.1093\/emboj\/18.4.882"},{"key":"2020021223261107300_R85","doi-asserted-by":"crossref","unstructured":"Carmeliet P, Lampugnani M-G, Moons L, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 1999;98:147\u2013157.","DOI":"10.1016\/S0092-8674(00)81010-7"},{"key":"2020021223261107300_R86","doi-asserted-by":"crossref","unstructured":"Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Ann Rev Cell Dev Biol. 1999;15:551\u2013578.","DOI":"10.1146\/annurev.cellbio.15.1.551"},{"key":"2020021223261107300_R87","doi-asserted-by":"crossref","unstructured":"Salceda S, Caro J. Hypoxia-inducible factor 1a (HIF-1a) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997;272:22642\u201322647.","DOI":"10.1074\/jbc.272.36.22642"},{"key":"2020021223261107300_R88","unstructured":"Yu F, White S, Zhao Q, Lee F. Dynamic, site-specific interaction of hypoxia-inducible factor-1a with the von Hippel-Lindau tumor suppressor protein. Cancer Res. 2001;61:4136\u20134142."},{"key":"2020021223261107300_R89","doi-asserted-by":"crossref","unstructured":"Kerbel RS, Viloria-Petit A, Okada F, Rak J. Establishing a link between oncogenes and tumor angiogenesis. Mol Med. 1998;4:286\u2013295.","DOI":"10.1007\/BF03401737"},{"key":"2020021223261107300_R90","doi-asserted-by":"crossref","unstructured":"Okada F, Rak JW, St Croix B, et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up- regulation of vascular endothelial growth factor\/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci U S A. 1998;95:3609\u20133614.","DOI":"10.1073\/pnas.95.7.3609"},{"key":"2020021223261107300_R91","doi-asserted-by":"crossref","unstructured":"Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A. 1997;94:861\u2013866.","DOI":"10.1073\/pnas.94.3.861"},{"key":"2020021223261107300_R92","doi-asserted-by":"crossref","unstructured":"Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1a. Genes Dev. 2000;14:34\u201344.","DOI":"10.1101\/gad.14.1.34"},{"key":"2020021223261107300_R93","doi-asserted-by":"crossref","unstructured":"Guillemin K, Drasnow MA. The hypoxic response: Huffing and HIFing. Cell. 1997;89:9\u201312.","DOI":"10.1016\/S0092-8674(00)80176-2"},{"key":"2020021223261107300_R94","doi-asserted-by":"crossref","unstructured":"Marshall C. The embryonic origins of human haematopoiesis [review]. Br J Haematol. 2001;112:838\u2013850.","DOI":"10.1046\/j.1365-2141.2001.02537.x"},{"key":"2020021223261107300_R95","doi-asserted-by":"crossref","unstructured":"Eichmann A, Corbel C, Nataf V, Vaigot P, Breant C, Le Douarin NM. Ligand-dependent development of the endothelial and hemapoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc Natl Acad Sci U S A. 1997;94:5141\u20135146.","DOI":"10.1073\/pnas.94.10.5141"},{"key":"2020021223261107300_R96","doi-asserted-by":"crossref","unstructured":"Gunsilius E, Duba H-C, Petzer A, et al. Evidence from leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet. 2000;355:1688\u20131691.","DOI":"10.1016\/S0140-6736(00)02241-8"},{"key":"2020021223261107300_R97","doi-asserted-by":"crossref","unstructured":"Gao Z, McAlister V, Williams G. Repopulation of liver endothelium by bone-marrow-derived cells. Lancet. 2001;357:932\u2013933.","DOI":"10.1016\/S0140-6736(00)04217-3"},{"key":"2020021223261107300_R98","doi-asserted-by":"crossref","unstructured":"Ikpeazu C, Davidson M, Halteman D, Goodman S, Browning P, Brandt S. Donor origin of circulating endothelial progenitors after allogeneic bone marrow transplantation. Biology of Blood and Marrow Transplantation. 2000;6:301\u2013308.","DOI":"10.1016\/S1083-8791(00)70055-3"},{"key":"2020021223261107300_R99","doi-asserted-by":"crossref","unstructured":"Peichev M, Naiyer A, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood. 2000;95:952\u2013958.","DOI":"10.1182\/blood.V95.3.952.003k27_952_958"},{"key":"2020021223261107300_R100","doi-asserted-by":"crossref","unstructured":"Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.Blood. 1998;92:4150\u20134166.","DOI":"10.1182\/blood.V92.11.4150"},{"key":"2020021223261107300_R101","doi-asserted-by":"crossref","unstructured":"Tordjman R, Delaire S, Plouet J, et al. Erythroblasts are a source of angiogenic factors. Blood. 2001;97:1968\u20131974.","DOI":"10.1182\/blood.V97.7.1968"},{"key":"2020021223261107300_R102","doi-asserted-by":"crossref","unstructured":"Broxmeyer HE, Cooper S, Li ZH, et al. Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor. Int J Hematol. 1995;62:203\u2013215.","DOI":"10.1016\/0925-5710(95)00412-2"},{"key":"2020021223261107300_R103","doi-asserted-by":"crossref","unstructured":"Gerber H-P, Vu TH, Ryan AM, Dowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999;5:623\u2013628.","DOI":"10.1038\/9467"},{"key":"2020021223261107300_R104","doi-asserted-by":"crossref","unstructured":"Niida S, Kaku M, Amano H, et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med. 1999;190:293\u2013298.","DOI":"10.1084\/jem.190.2.293"},{"key":"2020021223261107300_R105","unstructured":"Kuramoto K, Uesaka T, Kimura A, Kobayashi M, Watanabe H, Katoh O. ZK7, a novel zinc finger gene, is induced by vascular endothelial growth factor and inhibits apoptotic death in hematopoietic cells. Cancer Research. 2000;60:425\u2013430."},{"key":"2020021223261107300_R106","unstructured":"Katoh O, Takahashi T, Oguri T, et al. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an anti-apoptotic factor. Cancer Research. 1998;58:5565\u20135569."},{"key":"2020021223261107300_R107","unstructured":"Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Research. 1995;55:5687\u20135692."},{"key":"2020021223261107300_R108","doi-asserted-by":"crossref","unstructured":"Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870\u20131875.","DOI":"10.1182\/blood.V89.6.1870"},{"key":"2020021223261107300_R109","doi-asserted-by":"crossref","unstructured":"Bellamy W, Richter L, Dirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97:1427\u20131434.","DOI":"10.1182\/blood.V97.5.1427"},{"key":"2020021223261107300_R110","unstructured":"List AF, Glinsmann-Gibson B, Stadheim C, Meuillet E, Bellamy W, Powis G. VEGFR-1 (Flt-1) and VEGFR-2 (KDR) stimulate the proliferation of AML cells via the P13-kinase and Akt\/protein kinase-b (PKB) signal pathway. Blood. 2000;96:301a."},{"key":"2020021223261107300_R111","doi-asserted-by":"crossref","unstructured":"Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest2000;106:511\u2013521.","DOI":"10.1172\/JCI8978"},{"key":"2020021223261107300_R112","doi-asserted-by":"crossref","unstructured":"Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240\u20132245.","DOI":"10.1182\/blood.V96.6.2240"},{"key":"2020021223261107300_R113","doi-asserted-by":"crossref","unstructured":"Krejci P, Dvorakova D, Krahulcova E. et al. FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias. Leukemia. 2001;15:228\u2013237.","DOI":"10.1038\/sj.leu.2402012"},{"key":"2020021223261107300_R114","doi-asserted-by":"crossref","unstructured":"Plowright E, Li Z, Bergsagel L, et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood. 2000;95:992\u2013998.","DOI":"10.1182\/blood.V95.3.992.003k29_992_998"},{"key":"2020021223261107300_R115","doi-asserted-by":"crossref","unstructured":"Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood. 2000;96:3712\u20133718.","DOI":"10.1182\/blood.V96.12.3712"},{"key":"2020021223261107300_R116","doi-asserted-by":"crossref","unstructured":"Foss HD, Araujo A, Demel G, Klotzbach H, Hummel M, Stein H. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol. 1997:183:44\u201350.","DOI":"10.1002\/(SICI)1096-9896(199709)183:1<44::AID-PATH1103>3.0.CO;2-I"},{"key":"2020021223261107300_R117","unstructured":"Bellamy WT, Richter L, Frutiger Y, et al. Expression of vascular endothelial cell growth factor (VEGF) and its receptors in non-Hodgkin's lymphoma (NHL). Proc Amer Assoc Cancer Res. 1999;40:227."},{"key":"2020021223261107300_R118","doi-asserted-by":"crossref","unstructured":"Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717\u20133721.","DOI":"10.1182\/blood.V94.11.3717"},{"key":"2020021223261107300_R119","unstructured":"Fusetti L, Pruneri G, Gobbi A, et al. Human myeloid and lymphoid malignancies in the non-obese diabetic\/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res. 2000;60:2527\u20132534."},{"key":"2020021223261107300_R120","doi-asserted-by":"crossref","unstructured":"Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565\u20131571.","DOI":"10.1056\/NEJM199911183412102"},{"key":"2020021223261107300_R121","unstructured":"Price A, Shi Q, Morris D, et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clinical Cancer Research. 1999;5:845\u2013854."},{"key":"2020021223261107300_R122","doi-asserted-by":"crossref","unstructured":"Gearing AJH, Beckett P, Christodoulou M, et al. Processing of tumor necrosis factor-\u03b1 precursor by metalloproteinases. Nature. 1994;370:555\u2013557.","DOI":"10.1038\/370555a0"},{"key":"2020021223261107300_R123","doi-asserted-by":"crossref","unstructured":"Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumor necrosis factor-alpha from cells. Nature. 1997;385:729\u2013733.","DOI":"10.1038\/385729a0"},{"key":"2020021223261107300_R124","doi-asserted-by":"crossref","unstructured":"Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777\u20131783.","DOI":"10.1084\/jem.182.6.1777"},{"key":"2020021223261107300_R125","doi-asserted-by":"crossref","unstructured":"D'Amato RJ, Loughman MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082\u20134085.","DOI":"10.1073\/pnas.91.9.4082"},{"key":"2020021223261107300_R126","doi-asserted-by":"crossref","unstructured":"Corral LG, Haslett PAJ, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs that are potent inhibitors of TNF-\u03b1. J Immunol. 1999;163:380\u2013386.","DOI":"10.4049\/jimmunol.163.1.380"},{"key":"2020021223261107300_R127","doi-asserted-by":"crossref","unstructured":"Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943\u20132950.","DOI":"10.1182\/blood.V96.9.2943"},{"key":"2020021223261107300_R128","doi-asserted-by":"crossref","unstructured":"Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cytotoxicity in multiple myeloma. Blood. 2001;98:210-216,","DOI":"10.1182\/blood.V98.1.210"},{"key":"2020021223261107300_R129","doi-asserted-by":"crossref","unstructured":"Raza A, Meyer P, Dutt T, et al. Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes. Blood2001;9:958\u2013965.","DOI":"10.1182\/blood.V98.4.958"},{"key":"2020021223261107300_R130","doi-asserted-by":"crossref","unstructured":"Shi YP, Ferrara N. Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking vascular endothelial growth factor (VEGF). Biochem Biophys Res Commun. 1999;254:480\u2013483.","DOI":"10.1006\/bbrc.1998.9966"},{"key":"2020021223261107300_R131","doi-asserted-by":"crossref","unstructured":"Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial. Blood. 2001;97:3361\u20133369.","DOI":"10.1182\/blood.V97.11.3361"},{"key":"2020021223261107300_R132","doi-asserted-by":"crossref","unstructured":"Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood. 2001;97:1413\u20131421.","DOI":"10.1182\/blood.V97.5.1413"},{"key":"2020021223261107300_R133","doi-asserted-by":"crossref","unstructured":"Mesters RM, Padro T, Bieker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood. 2001;98:241\u2013243.","DOI":"10.1182\/blood.V98.1.241"},{"key":"2020021223261107300_R134","doi-asserted-by":"crossref","unstructured":"Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95:309\u2013313.","DOI":"10.1182\/blood.V95.1.309"},{"key":"2020021223261107300_R135","doi-asserted-by":"crossref","unstructured":"Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637\u20132644.","DOI":"10.1182\/blood.V95.8.2637"},{"key":"2020021223261107300_R136","doi-asserted-by":"crossref","unstructured":"Janawska-Wieczorek A, Marquuez LA, Matsuzaki A, et al. Expression of matrix metalloproteinases (MMP-2 and \u20139) and tissue inhibitors of metalloproteinases (TIMP-1 and \u20132) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J Hematol. 1999;105:402\u2013411.","DOI":"10.1111\/j.1365-2141.1999.01352.x"},{"key":"2020021223261107300_R137","doi-asserted-by":"crossref","unstructured":"Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999;81:1398\u20131401.","DOI":"10.1038\/sj.bjc.6693515"},{"key":"2020021223261107300_R138","unstructured":"Arimura K, Atima N, Ohtsubo H, et al. Matrix metalloproteinase inhibitor inhibits apoptosis induction of MDS bone marrow cells. 1999;94:105a."},{"key":"2020021223261107300_R139","doi-asserted-by":"crossref","unstructured":"Mesa RA, Hanson CA, Rajkumar V, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000;96:3374\u20139980.","DOI":"10.1182\/blood.V96.10.3374"},{"key":"2020021223261107300_R140","unstructured":"Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clinical Cancer Research. 2000;6:3111\u20133116."},{"key":"2020021223261107300_R141","doi-asserted-by":"crossref","unstructured":"Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064\u20133073.","DOI":"10.1182\/blood.V93.9.3064"},{"key":"2020021223261107300_R142","doi-asserted-by":"crossref","unstructured":"Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine trumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630\u20132636.","DOI":"10.1182\/blood.V95.8.2630"},{"key":"2020021223261107300_R143","doi-asserted-by":"crossref","unstructured":"Kuittinen O, Savolainen E-R, Koistinen P, Mottonen M, Turpeenniemi-Hujanen T. MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leukemia Research. 2001;25:125\u2013132.","DOI":"10.1016\/S0145-2126(00)00104-1"},{"key":"2020021223261107300_R144","unstructured":"Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815\u2013821."},{"key":"2020021223261107300_R145","doi-asserted-by":"crossref","unstructured":"Bertolini F, Paolucci M, Peccatori F, et al. Angiogenic growth factors and Endostatin in non-Hodgkin's lymphoma. Br J Hematol. 1999;106:504\u2013509.","DOI":"10.1046\/j.1365-2141.1999.01547.x"},{"key":"2020021223261107300_R146","doi-asserted-by":"crossref","unstructured":"Vacca A, Ribatti D, Ruco L, et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphoma. Br J Cancer. 1999;79:965\u2013970.","DOI":"10.1038\/sj.bjc.6690154"},{"key":"2020021223261107300_R147","doi-asserted-by":"crossref","unstructured":"Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell lymphocytic leukemia. Leukemia. 2000;14:1414\u20131418.","DOI":"10.1038\/sj.leu.2401825"},{"key":"2020021223261107300_R148","doi-asserted-by":"crossref","unstructured":"Molica S, Vitelli G, Levato D, Gandolfo GM, Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Heamatol. 1999;107:605\u2013610.","DOI":"10.1046\/j.1365-2141.1999.01752.x"},{"key":"2020021223261107300_R149","doi-asserted-by":"crossref","unstructured":"Chen H, Treweeke AT, West DC, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood. 2000;96:3181\u20133187.","DOI":"10.1182\/blood.V96.9.3181"},{"key":"2020021223261107300_R150","doi-asserted-by":"crossref","unstructured":"Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 1999;362:841\u2013844.","DOI":"10.1038\/362841a0"},{"key":"2020021223261107300_R151","doi-asserted-by":"crossref","unstructured":"Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human ant-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncology. 2001;19:843\u2013850.","DOI":"10.1200\/JCO.2001.19.3.843"},{"key":"2020021223261107300_R152","doi-asserted-by":"crossref","unstructured":"Tulple A, Scadden DT, Espina BM, et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000;18:716\u2013723.","DOI":"10.1200\/JCO.2000.18.4.716"},{"key":"2020021223261107300_R153","unstructured":"Dinney CPN, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-\u03ba adminstration. Cancer Res. 1998;58:808\u2013814."},{"key":"2020021223261107300_R154","unstructured":"Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR\/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 2000;60:5117\u20135124."},{"key":"2020021223261107300_R155","unstructured":"Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999;59:5209\u20135218."},{"key":"2020021223261107300_R156","doi-asserted-by":"crossref","unstructured":"Sandberg JA, Parker VP, Blanchard KS, et al. Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J Clin Pharm. 2000;40:1462\u20131469.","DOI":"10.1177\/009127000004001217"},{"key":"2020021223261107300_R157","unstructured":"Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99\u2013106."},{"key":"2020021223261107300_R158","unstructured":"Drevs J, Hofmann I, Hugenschmidt H, et al. Effects of PTK787\/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 2000;60:4819\u20134824."},{"key":"2020021223261107300_R159","unstructured":"Kumar CC, Malkowski M, Yin Z, et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual \u03b1v\u03b23 and \u03b1v\u03b25 integrin receptor antagonist. Cancer Res. 2001;61:2232\u20132238."},{"key":"2020021223261107300_R160","doi-asserted-by":"crossref","unstructured":"Kerr JS, Slee MA, Mousa SA. Small molecule av integrin antagonists: novel anticancer agents. Expert Opin Investig Drugs. 2000;9:1271\u20131279.","DOI":"10.1517\/13543784.9.6.1271"},{"key":"2020021223261107300_R161","unstructured":"Kim Y-M, Jang J-W, Lee O-H, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase 2. Cancer Res. 2000;60:5410\u20135413."},{"key":"2020021223261107300_R162","doi-asserted-by":"crossref","unstructured":"O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277\u2013285.","DOI":"10.1016\/S0092-8674(00)81848-6"},{"key":"2020021223261107300_R163","doi-asserted-by":"crossref","unstructured":"Pike SE, Yao L, Setsuda J, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med. 1998;188:2349\u20132356.","DOI":"10.1084\/jem.188.12.2349"},{"key":"2020021223261107300_R164","unstructured":"Logothetis CJ, Wu KK, Finn LD, et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clinical Cancer Research. 2001;7:1198\u20131203."},{"key":"2020021223261107300_R165","doi-asserted-by":"crossref","unstructured":"Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature. 1994;368:237\u2013239.","DOI":"10.1038\/368237a0"},{"key":"2020021223261107300_R166","unstructured":"Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res. 1999;59:6033\u20136037."},{"key":"2020021223261107300_R167","doi-asserted-by":"crossref","unstructured":"Reichert A, Heisterkamp N, Daley GQ, Groffen J. Treatment of Bcr\/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood. 2001;97:1399\u20131403.","DOI":"10.1182\/blood.V97.5.1399"},{"key":"2020021223261107300_R168","doi-asserted-by":"crossref","unstructured":"Peters DG, Hoover RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR\/Abl-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404\u20131412.","DOI":"10.1182\/blood.V97.5.1404"},{"key":"2020021223261107300_R169","doi-asserted-by":"crossref","unstructured":"Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89:2067\u20132078.","DOI":"10.1182\/blood.V89.6.2067"},{"key":"2020021223261107300_R170","doi-asserted-by":"crossref","unstructured":"Rimokh R, Berger F, Delsol G, et al. Rearrangement and overexpression of the BCL1\/PRAD1 gene in intermediate lymphocytic lymphomas and in t(11q13)bearing leukemias. Blood. 1993;81:3063\u20133067.","DOI":"10.1182\/blood.V81.11.3063.3063"},{"key":"2020021223261107300_R171","doi-asserted-by":"crossref","unstructured":"Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphomas are associated with variant cytology and predict a poor prognosis. Blood. 1996;87:4302\u20134310.","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302"},{"key":"2020021223261107300_R172","unstructured":"Bible KC, Kaurmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L868275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. 1997;57:3375\u20133380."},{"key":"2020021223261107300_R173","doi-asserted-by":"crossref","unstructured":"Ko\u0308nig A, Schwartz GK, Mohammed RM, Al-Katib A, Gabrilove JL. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl2 and induces growth arrest and apoptosis in chronic B-cell leukemia cell lines. Blood. 1997;90:4307\u20134312.","DOI":"10.1182\/blood.V90.11.4307"},{"key":"2020021223261107300_R174","unstructured":"Byrd JC, Shinn CA, Bedi A, et al. Flavopiridol has marked in vitro activity against B-chronic lymphocytic leukemia (BCLL) and induces apoptosis independent of p53 status. Blood. 1997;90(suppl 1):531a (abstr 2366)."},{"key":"2020021223261107300_R175","doi-asserted-by":"crossref","unstructured":"Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase3 without evidence of bcl2 modulation or dependence on functional p53. Blood. 1998;92:3804\u20133816.","DOI":"10.1182\/blood.V92.10.3804"},{"key":"2020021223261107300_R176","doi-asserted-by":"crossref","unstructured":"Parker BW, Kaur G, Nieves-Niera W, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood. 1998;91:458\u2013465.","DOI":"10.1182\/blood.V91.2.458"},{"key":"2020021223261107300_R177","doi-asserted-by":"crossref","unstructured":"Achenbach TV, Mu\u0308ller R, Slater EP. BCL2 independence of flavopiridolinduced apoptosis. J Biol Chem. 2000;275:32089\u201332097.","DOI":"10.1074\/jbc.M005267200"},{"key":"2020021223261107300_R178","doi-asserted-by":"crossref","unstructured":"Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine downregulate antiapoptosis proteins in B cell chronic lymphocytic leukemia. Blood. 2000;96:393\u2013397.","DOI":"10.1182\/blood.V96.2.393"},{"key":"2020021223261107300_R179","unstructured":"Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, Senderowicz AM. Flavopiridol, a protein kinase inhibitor, downregulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res. 1999;59:5433\u20135437."},{"key":"2020021223261107300_R180","unstructured":"Arguello F, Alexander M, Sterry JA, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood. 1998;91:2482\u20132490."},{"key":"2020021223261107300_R181","unstructured":"Innocenti F, Stadler W, Iyer L, Rami\u0301rez J, Vokes EE, Ratain MJ. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res. 2000;6:3400\u20133405."},{"key":"2020021223261107300_R182","unstructured":"Maki C, Huibregtse J, Howley P. In vivo ubiquination and proteasome-mediated degradation of p53. Cancer Res. 1996;56:2649\u20132654."},{"key":"2020021223261107300_R183","unstructured":"Yoshida H, Kitamura K, Tanaka K, et al. Accelerated degradation of PML-retinoic acid receptor a (PML RAR\u03b1 by all trans retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res. 1996;56:2945\u20132948."},{"key":"2020021223261107300_R184","unstructured":"Adams J, Stein R. Novel inhibitors of the proteasome and their therapeutic use in inflammation. Ann Rep Med Chem. 1996;31:279\u2013288."},{"key":"2020021223261107300_R185","unstructured":"Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615\u20132622."},{"key":"2020021223261107300_R186","doi-asserted-by":"crossref","unstructured":"Beg AA, Baltimore D. An essential role for NF-\u03baB in preventing TNFa induced cell death. Science. 1996;274:782\u2013784.","DOI":"10.1126\/science.274.5288.782"},{"key":"2020021223261107300_R187","unstructured":"Wang CVY, Cusack JC, Liu R. Control of inducible chemoresistance: enhanced antitumor therapy through increased apoptosis by inhibition of NF\u03baB. Nature. 1999;5:412\u2013417."},{"key":"2020021223261107300_R188","unstructured":"Lin ZP, Boller YC, Amer SM, et al. Prevention of brefeldin-induced resistance to teniposide by the proteasome inhibitor MG132: involvement of NF-\u03baB activation in drug resistance. Cancer Res. 1998;58:3059\u20133065."},{"key":"2020021223261107300_R189","doi-asserted-by":"crossref","unstructured":"Soglio D, Servida F, Delia D, et al. The apoptogenic response of human myeloid leukaemia cells and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol. 2001;113:126\u2013136.","DOI":"10.1046\/j.1365-2141.2001.02683.x"},{"key":"2020021223261107300_R190","unstructured":"Orlowski RZ, Eswara JR, Larond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 1998;58:4342-4348,"},{"key":"2020021223261107300_R191","unstructured":"Hideshima T, Richardson P, Chauhan D, et al. The proteasome 6-inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071\u20133076."},{"key":"2020021223261107300_R192","doi-asserted-by":"crossref","unstructured":"Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 2000;95:619\u2013626.","DOI":"10.1182\/blood.V95.2.619"},{"key":"2020021223261107300_R193","doi-asserted-by":"crossref","unstructured":"Masdehors P, Omura S, MerleBeral H, et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasime-specific inhibitor lactacystin. Br J Haemtaol. 1999;105:752\u2013757.","DOI":"10.1046\/j.1365-2141.1999.01388.x"},{"key":"2020021223261107300_R194","unstructured":"Delic J, Masdehors P, Omura S, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF \u03b1-initiated apoptosis. Br J Cancer. 1999;77:375\u2013376."},{"key":"2020021223261107300_R195","doi-asserted-by":"crossref","unstructured":"Delic J, Masdehors P, Omura S, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human CLL lymphocytes to TNF \u03b1-induced apoptosis. Br J Cancer. 1998;77:1103\u20131107.","DOI":"10.1038\/bjc.1998.183"},{"key":"2020021223261107300_R196","doi-asserted-by":"crossref","unstructured":"Masdehors P, MerleVBeral H, Magdelenat H, Delic J. Ubiquitin proteasome system and increased susceptibility of BCLL lymphocytes to apoptotic death activation. Leuk Lymphoma. 2000;38(56):499\u2013504.","DOI":"10.3109\/10428190009059268"},{"key":"2020021223261107300_R197","doi-asserted-by":"crossref","unstructured":"Chandra J, Niemer I, Gilbreath J, et al. Proteasome inhibitors induce apoptosis in glucocorticoid resistant chronic lymphocytic leukemia lymphocytes. Blood. 1998;92:42204229.","DOI":"10.1182\/blood.V92.11.4220"},{"key":"2020021223261107300_R198","unstructured":"Stinchcombe TE, Mitchell BS, Depcik V, et al. PS341 is active in multiple myeloma: preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies. Blood. 2000;96(suppl 1):516a (abstr 2219)."},{"key":"2020021223261107300_R199","unstructured":"Nix D, Pien C, Newman R, et al. Clinical development of a proteasome inhibitor, PS341, for the treatment of cancer. Proc ASCO. 2001;20:86 (abstr 339)"},{"key":"2020021223261107300_R200","doi-asserted-by":"crossref","unstructured":"Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. Clin Oncol. 1999;17:1244\u20131253.","DOI":"10.1200\/JCO.1999.17.4.1244"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2001\/1\/443\/1713079\/443.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2001\/1\/443\/1713079\/443.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T21:01:22Z","timestamp":1682542882000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2001\/1\/443\/18627\/Rational-Approaches-to-Design-of-Therapeutics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1,1]]},"references-count":200,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2001.1.443","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1,1]]}}}